← Leaderboards
Allyson Ocean
Weill Medical Coll Of Cornell Univ
$102,080
Attributed
$102,080
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $91.6K · FY2006–07$100K$75K$50K$25K$0
'06
'07
Funding mix
By agency
NIH$102,080 · 7
By mechanism
M01$102,080 · 7
Top collaborators
No co-investigators on record.
Most similar at Weill Medical Coll Of Cornell Univ
Same institution · by research overlap
- Fernando J Martinez$34,787,404
- Steven Monroe Lipkin$27,661,021
- Pengbo Zhou$14,509,570
- Jihye Paik$3,968,970
- James E Galvin$66,836,874
Others in their field
Top investigators on “United States National Institutes Of Health”
- Leonard Freedman · Leidos Biomedical Research, Inc.$816,847,401
- Sonia M Thomas · Research Triangle Institute$701,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$642,073,624
- Bambra Strokes · Ppd Development Lp$526,656,217
- Lawrence Corey · Fred Hutchinson Cancer Center$513,687,120
- Tracy L Nolen · Research Triangle Institute$474,487,152
Research focus
United States National Institutes Of HealthComputer Retrieval Of Information On Scientific Projects DatabaseFundingGrantInstitutionResearch PersonnelResourcesResponseSourceToxic EffectRateRecoveryAdenocarcinomaSurvival RateComb Animal StructureGemcitabineBevacizumab/CetuximabIrinotecanMalignant Neoplasm Of PancreasPatternPrimary NeoplasmRandomizedTriapineTumor
Grant awards (7)
PHASE II TRIAL OF FOLFOX6, BEVACIZUMAB AND CETUXIMAB IN PATIENTS$6,407
M01 · FY2007 · RR · contact PI
A RANDOMIZED PHASE II STUDY OF BEVACIZUMAB (NSC# 704865) AND GEMCITABINE IN COMB$2,697
M01 · FY2007 · RR · contact PI
PHASE II STUDY PS341 ALONE OR COMB W/ IRINOTECAN IN PATIENTS W/ ADENOCARCINOMA$1,268
M01 · FY2007 · RR · contact PI
PHII TRIAPINE W/ GEMCITABINE ADENOCARCINOMA OF BILIARY DUCTS AND GALL BLADDER$152
M01 · FY2007 · RR · contact PI
NCI 5611: PHASE II STUDY OF BEVACIZUMAB (RHUMAB-VEGF) IN HEPATOCELLULAR CANCER$49,424
M01 · FY2006 · RR · contact PI
PHASE II TRIAL OF FOLFOX6, BEVACIZUMAB AND CETUXIMAB IN PATIENTS$37,271
M01 · FY2006 · RR · contact PI
A RANDOMIZED PHASE II STUDY OF BEVACIZUMAB (NSC# 704865) AND GEMCITABINE IN COMB$4,861
M01 · FY2006 · RR · contact PI